RxDoctor Payments Data

Carol Lai, MD

Internal Medicine · Boston, MANPI 1366889826

Payments from drug & device makers

$3,733in general payments, 2019–2025

Across 129 payments — averaging $28.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$799
  • E.r. Squibb & Sons, L.L.C.$545
  • Cvrx, Inc.$373
  • Boehringer Ingelheim$370
  • Abbott$323
  • Bridgebio Pharma, Inc.$253
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,733100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,733 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$143,317
Medicare patients
1,013
Services billed
2,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis150$3,854,872
EntrestoSacubitril/Valsartan386$645,554
JardianceEmpagliflozin387$591,463
EliquisApixaban309$429,225
CamzyosMavacamten44$373,691
VyndaqelTafamidis Meglumine13$283,620
FarxigaDapagliflozin Propanediol61$81,637
Repatha SureclickEvolocumab69$63,249
XareltoRivaroxaban44$56,755
Praluent PenAlirocumab15$11,011
Metoprolol Succinate480$9,448
Atorvastatin Calcium268$8,329
Carvedilol363$4,548
Flecainide Acetate47$4,519
Rosuvastatin Calcium114$4,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis, Vyndaqel$97$4,567,717472 claims
Boehringer IngelheimJardiance$370$591,463387 claims
E.r. Squibb & Sons, L.L.C.Camzyos$545$373,69144 claims
AstraZenecaFarxiga$232$81,63761 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →